23andMe, a consumer genetic testing company, plans to launch a GLP-1 weight loss telehealth membership through its Lemonaid Health business by the end of the month. The service will enable members to be prescribed and receive brand-name or compounded semaglutide medications.

The new offering will allow customers to access weight loss management services, fitting into the company's strategy of delivering services to improve individual health through preventive actions. 23andMe also plans to roll out a large-scale genetic research study to help identify the genetic mechanisms that may drive the efficacy and potential side effects of GLP-1 medications.

According to CEO Anne Wojcicki, the company believes this addition will create longitudinal value to help members remain focused on improving their health. 23andMe aims to leverage its unique research model and large customer base to quickly scale the study through outreach to millions of customers who have consented to participate in research.

Analyst QuickTake : 23andMe’s Lemonaid Health is the most recent telehealth provider beginning to offer and enable access to the GLP-1 weight loss medication. Recently, in May 2024, both Ro and Hims & Hers began expanding access to the medication. However, while the medication is rapidly gaining popularity, physicians have noted that it is not a "silver bullet" that should be seen as the cure for the obesity crisis in the US. Due to GLP-1’s side effects, cost, and results, the treatment is claimed to be only sustainable for two to three years. As such, 23andMe’s planned genetic research study on the drug could shed more light on the treatment, either further validating its potential or helping support why more restraint should be exercised when prescribing the medication.